Professional Documents
Culture Documents
Other: Hypersensitivity
reactions, overgrowth of
nonsusceptible organisms.
Musculoskeletal: Muscle
cramps, myalgia, back or leg
pain
Other: Angioedema
GU:UTI
Hematologic: Anemia
Metabolic: Hyperkalemia,
hypoglycemia, hyponatremia,
weight gain
Skin: Cellulitis
Skin: Rash
Other: Anaphylaxis,
gynecomastia, breast
soreness, drug fever
8.2
Drug Class MOA Representative Nursing Considerations
Agents
Monitoring
● Side effects
● Therapy effectiveness:
absence of infection,
normalized vital signs,
decreased pain
Patient Education:
● Purpose of the
medication: eliminate the
bacteria causing their
infection
● Take with a full glass of
water, with or without food
● Take either two hours
before or six hours after
dairy products, mineral
supplements, or antacids
● Stay well hydrated; drink
at least 2,000 mL of fluid
daily
● Completing the entire
course of treatment
● Side effects to report
Macrolides Macrolides stop Azithromycin Side Effects:
bacterial growth by (Zithromax) ● CNS: headache, seizures
inhibiting protein ● CV: QT prolongation,
synthesis Roxithromycin torsades de pointes (rare)
(Roxistat) ● EENT: ototoxicity
● GI: nausea, vomiting,
diarrhea, abdominal pain,
Clostridioides difficile
infection (CDI),
hepatotoxicity
● GU: vaginitis, candidiasis
● INTEG: skin rash
● SYST: angioedema,
Stevens-Johnson
syndrome, toxic
epidermal necrolysis
● Erythromycin: esophagitis
● Azithromycin:
thrombocytopenia (rare)
● Clarithromycin: abnormal
taste, pancreatitis
Monitoring
● Side effects
● Infection resolution
● Absence of symptoms
Client education
● Purpose of medication:
treat infection
● Dose: one tablet taken
with or without food
● Abstain from sexual
activity for seven days,
starting after the
completion of therapy
● Side effects to report
Lincosamides They prevent Lincomycin Side Effects:
bacterial replication ● Nausea, vomiting,
by interfering with Clindamycin diarrhea, abdominal
the protein (Clindal) cramps
synthesis and may ● Serious hypersensitivity
also demonstrate reactions:
bactericidal (kill Stevens-Johnson
bacteria) activity syndrome, exfoliative
against certain dermatitis
organisms at high ● Injection site reactions
antibiotic ● Intravaginal
concentrations. administration: redness,
burning, itching, vaginal
candidiasis
Contraindications:
● Pregnancy and
breastfeeding
● GI disease
- Colitis
- Enteritis
Monitoring:
● Patient IV
● Signs of infiltration
● Hypersensitivity reaction
● CDI
● Evaluate therapeutic
response
Client education
Contraindications and
Cautions
● Known allergy to
cephalosporins and
bea-lacams.
● Hepatic or renal
impairment.
● Pregnancy and lactation.
Client Education:
● If a client experiences
fever and bloody
diarrhoea, they should
contact the provider
immediately.
● The client should also be
advised that side effects
can occur even weeks
after the medication is
discontinued.
Client Education:
● Instruct patient to take
medication exactly as
directed evenly spaced
times between doses,
even if feeling better. Do
not skip doses or double
up on missed doses. If a
dose is missed, take as
soon as remembered if
not almost time for the
next dose.
● Caution patient or other
activities requiring
alertness until response
to medication is known.
● Inform the patient that
medication may cause an
unpleasant metallic taste.
● Inform the patient that
medication may cause
urine to turn dark.
● Advise patient to consult
health care professional if
no improvement in a few
days or if signs and
symptoms of
superinfection (black furry
overgrowth on tongue;
loose or foul-smelling
stools develop)
Contraindications and
Cautions:
● Pregnancy,
breastfeeding, newborns
● G6PD deficiency, acute
porphyria
● Inhibitor of the
cytochrome p450 family:
toxicity (e.g., warfarin,
sulfonylureas, phenytoin)
● Decreases the effect of
ceftazidime, estriol, and
vitamin B12
Client Education:
● Administered IV every six
hours
Client Education:
● Patients should be
counseled to take
medications as directed
for the full course of
antibacterial therapy.
● They should monitor for
side effects such as
hypersensitivity, tinnitus,
hearing loss, and vertigo.
● Patients should promptly
follow-up with their
healthcare provider if no
improvement in
symptoms is identified